

Anders Waage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10932541/publications.pdf>

Version: 2024-02-01

17
papers

2,017
citations

687363

13
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

2292
citing authors

#	ARTICLE	IF	CITATIONS
1	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
2	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
3	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011, 118, 1239-1247.	1.4	243
4	Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. <i>Blood</i> , 2002, 100, 3002-3007.	1.4	227
5	Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts. <i>European Journal of Immunology</i> , 1990, 20, 2439-2443.	2.9	217
6	Cytokine regulation of interleukin 6 production by human endothelial cells. <i>Cellular Immunology</i> , 1989, 121, 372-382.	3.0	161
7	Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. <i>Blood</i> , 2001, 98, 2269-2271.	1.4	158
8	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	1.4	102
9	High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. <i>Blood</i> , 2000, 96, 3139-3146.	1.4	91
10	Regulation of interleukin-2 and interleukin-6 production from T-cells: Involvement of interleukin-1 \hat{I}^2 and transforming growth factor- \hat{I}^2 . <i>Cellular Immunology</i> , 1990, 126, 47-56.	3.0	82
11	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013, 98, 87-94.	3.5	73
12	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
13	Bone Disease in Multiple Myeloma. <i>Medical Oncology</i> , 2006, 23, 431-442.	2.5	14
14	Why do myeloma patients have bone disease? A historical perspective. <i>Blood Reviews</i> , 2020, 41, 100646.	5.7	13
15	Release of bioactive interleukin 6 but not of tumour necrosis factor- \hat{I}^{\pm} after elective cardiopulmonary bypass. <i>Perfusion (United Kingdom)</i> , 1993, 8, 233-238.	1.0	10
16	The Influence of Growth Hormone on Tumour Necrosis Factor and Neutrophil Leukocyte Function in Sepsis. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 393-399.	1.5	8
17	Bmps(Bone Morphogenetic Proteins) Inhibit Growth in Multiple Myeloma Cells by p53 Activation.. <i>Blood</i> , 2004, 104, 3354-3354.	1.4	0